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Abstract
Background and objective  Approximately 30% of patients who are diagnosed with non-small cell lung cancer (NSCLC) are 
classified as N2 on the basis of metastasis to the mediastinal lymph nodes. The effectiveness of surgery for these patients remains 
controversial. Although surgeries in recent years are proved to be effective to some extent, yet due to many reasons, 5-year 
survival rate after surgery varies greatly from patient to patient. Thus it is necessary to select patients who have a high probability 
of being be cured through an operation, who are suitable to receive surgery and the best surgical methods so as to figure out the 
conditions under which surgical treatment can be chosen and the factors that may influence prognosis. 
Methods  165 out of 173 patients with N2 NSCLC were treated with surgery in our department from January 1999 to May 2003, 
among whom 130 were male, 43 female and the sex ratio was 3:1, average age 53, ranging from 29 to 79. The database covers the 
patients’ complete medical history including the information of their age, sex, location and size of tumor, date of operation, surgical 
methods, histologic diagnosis, clinical stage, post-operative TNM stage, neoadjuvant treatment and chemoradiotherapy. The 
methods of clinical stage verification include chest X-ray, chest CT, PET, mediastinoscopy, bronchoscope (+?), brain CT or MRI, 
abdominal B ultrasound (or CT), and bone ECT. The pathological classification was based on the international standard for lung 
cancer (UICC 1997). Survival time was analyzed from the operation date to May 2008 with the aid of SPSS (Statistical Package for 
the Social Sciences) program. Kaplan-Meier survival analysis, Log-rank test and Cox multiplicity were adopted respectively to obtain 
patients’ survival curve, survival rate and the impact possible factors may have on their survival rate. 
Results  The median survival time was 22 months, with 3-year survival rate reaching 28.1% and 5-year survival rate reaching 
19.0%. Age, sex, different histological classification and postoperative chemoradiotherapy seem to have no correlation with 
5-year survival rate. In all N2 subtypes, 5-year survival rate is remarkably higher for unexpected N2 discovered at thoractomy and 
proven N2 stage before preoperative work-up and receive a mediastinal down-staging after induction therapy (P<0.01), reaching 
30.4% and 27.3% respectively. 5-year survival rate for single station lymph node metastasis were 27.8%, much higher compared 
with 9.3% for multiple stations (P<0.001). Induction therapy which downstages proven N2 in 73.3% patients gains them the 
opportunity of surgery. The 5-year survival rate were 23.6% and 13.0% for patients who had complete resection and those who 
had incomplete resection (P<0.001). Patients who underwent lobectomy (23.2%) have higher survival rate, less incidence rate of 
complication and mortality rate, compared with pneumonectomy (14.8%) (P<0.01). T4 patients has a 5-year survival rate as low 
as 11.1%, much less than T1 (31.5%) and T2 (24.3%) patients (P=0.01). It is noted through Cox analysis that completeness of 
resection, number of positive lymph node stations and primary T status have significant correlativity with 5-year survival rate.  
Conclusion  It is suggested that surgery (lobectomy preferentially) is the best solution for T1 and T2 with primary tumor 
have not invaded pleura or the distance to carina of trachea no less than 2 cm, unexpected N2 discovered at thoractomy 
when a complete resection can be applied, and proven N2 discovered during preoperative work-up and is down-staged after 
induction therapy. Surgical treatment is the best option, lobectomy should be prioritized in operational methods since ite rate 
of complication and morality are lower than that of pneumonectomy. Patients’ survival time will not benefit from surgery if they 
are with lymph nodes metastasis of multiple stations (Bulky N2 included) and T4 which can be partially removed. Neoadjuvant 
chemotherapy increases long-term survival rate of those with N2 proven prior to surgery. However, postoperative radiotherapy 
decreases local recurrence rate but does not contribute to patients’ long-term survival rate.
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Introduction
Approximately 30% of patients who are newly diagnosed 
with non-small cell lung cancer (NSCLC) are classified as N2 
on the basis of metastasis to the mediastinal lymph nodes. 
Their median survival time is 7 months. Chemoradiation 
therapy has limited effect. Surgery may bring about some posi-
tive results, yet the 5-year survival rate of different patients var-
ies greatly. Factors leading to the differences are ways to verify 
N2 (pre-surgery radiology, pathology before, during and after 
surgery), the degradation state of mediastinal lymph node me-
tastasis after chemotherapy, grade of resection, surgical meth-
ods, types of pathology, location and size of tumor, numbers of 
lymph nodes and post-operative adjuvant therapy. Therefore, 
it is necessary to select patients who have a high probability of 
being be cured through an operation, who are suitable to re-
ceive surgery and the best surgical methods. In this paper, N2 
is classified into 4 subgroups. The first group is unexpected N2 
(incidental or surprised N2), which belongs to period I or II 
clinical stage classification, yet is found out to be N2 matastasis 
through pathology after operation or single station mediastinal 
lymph node metastasis during operation. The second group is 
marginal or proven N2. There is mediastinal mass-like density 
on the basis of radiology before surgery, and single or multiple 
lymph node matastasis proven through mediastinotopy, PET/
CT, or lymph biopsy. The third group is Bulky N2 with short 
radius more than 2 cm or lymph matastasis of multiple sta-
tions. The fourth group is N2 with primary tumors as T4. We 
retrospectively analyzed the effect of the operations we had on 
173 patients at N2 period from 1999 to 2003, so as to identify 
the surgical indication and evaluate the prognostic factors. 
Common Data
380 patients with primary tumors had surgeries at thoracic 
surgery of China-Japan Friendship Hospital from January 1999 
to May 2003. Among them, 173 were proven N2 before or af-
ter the surgery through pathology, 165 of them had operation 
and 13 exploratory thoracotomy (7.9%). With 130 male and 
43 female, the sex ratio was 3:1. The average age of the patients 
were 53, ranging from 29 to 79. There were patients’ follow-up 
data and complete medical history including the information 
of their age, sex, location and size of tumor, date of operation, 
surgical methods, histological diagnosis, clinical stage, patho-
logic type, post-operative TNM stage, pre-surgical chemother-
apy, degradation after chemotherapy, cycles of chemotherapy 
after operations, radio therapy after operation, viable status and 
survival time. The lost to follow-up rate was 13%. The methods 
of clinical stage verification include Posterior to Anterior (PA) 
chest X-ray, chest CT, PET, mediastinoscopy, bronchoscope, 
brain CT, abdominal B ultrasound, and bone ECT. The patho-
logical classification was based on the international standard 
for lung cancer (UICC 1997).
Statistical analysis
Survival time was analyzed from the operation date to May 
2008 with the aid of SPSS (Statistical Package for the Social 
Sciences) program. Kaplan-Meier survival analysis, Log-rank 
test and Cox multiplicity were adopted respectively to obtain 
patients’ survival curve, survival rate and the impact possible 
factors may have on their survival rate.  
Results
Post-operative survival status 
The median survival time was 22 months, with the 3-year and 
5-year survival rates reaching 28.1% and 19.0% respectively. 
The correlation between patient characteristics and prognosis 
Factors such as age, gender, pathologic type, post-operative 
chemotherapy, post-operative radiotherapy appear to have a 
few relation with patients’ 5-year survival time (Tab 1). 5-year 
survival rate for those who had lobectomy was 23.6%, substan-
tially exceeding 13.0%, the rate of those who had pneumonec-
tomy (P<0.001) among (25%), the survival curve is showed 
in Fig 1. 5-year survival rate for T4 patients were 11.1%, much 
lower than that of T1 (31.5%) and T2 (24.3%) (P=0.01). This 
survival curve is in Fig 2. It can be seen in Tab 2 that the ratio 
of single station lymph node and the rate of complete resection 
of subgroup I and II are higher than that of subgroup III and 
IV. 5-year survival rate for the unexpected were 30.4%, and that 
of N2 stage proven before preoperative work-up and receive a 
mediastinal down-staging after induction therapy were 27.3%, 
significantly higher than other N2 subtypes (P<0.01). Induc-
tion therapy which downstages proven N2 in 73.3% patients 
gain them the opportunity of surgery. It is illustrated in Tab 3 
that the 5-year survival rate of patients who had lobectomy was 
(23.2%) have higher survival rate, less incidence rate of com-
plication and mortality rate, compared with pneumonectomy 
(14.8%).
Factors influencing prognosis 
It is noted through Cox analysis that completeness of resec-
tion, classification of T status and number of positive lymph 
node stations and have significant correlativity with 5-year sur-
vival rate (Tab 4).
Discussion
The prognosis of N2 stage NSCLC is unfavorable, and the 
outcome of surgery is limited, so the treatment strategy is high-
ly controversial all over the world. We evaluated several factors 
in our series and compared them with other reports in order 
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Tab 1  Relationship between the clinical data of 173 NSCLC cases and the long-time   
              survival rate 
Factors                                               Cases (%)   
              Survival rate (%)    
P 
                                                                 3-year          5-year  
Age                                                                       0.88
    ≤60                                                84 (48.6)  22.2  27.8 
    <60                                                89 (51.4)  33.3  12.5 
Sex                                                                       0.15
    Male                                             130 (75.1)  25.5  12.1 
    Female                                                43 (24.9)  40.0  44.4 
Operation                                                <0.001
    Complete resection   110 (66.7)  39.4  23.6 
    Uncertain resection     19 (11.5)  44.4  21.1 
    Uncomplete resection     23 (13.9)  25.3  13.0 
    Explore                                              13 (7.9)                      15.4  7.7 
T-stage                                                                       0.01
    T1                                                10 (5.8)                      47.9  31.5 
    T2                                                58 (33.5)  38.4  24.3 
    T3                                                59 (34.1)  32.2  18.4 
    T4                                                46 (26.6)  28.6  11.1 
Lymphnodes metastasis                           <0.001
    Single station                          91 (52.6)  48.4  27.8 
    Multiple stations                          82 (47.4)  19.5  9.3 
Pathological classification                             0.753
    Adenocarcinoma                          77 (44.5)  11.1  8.3 
    Squamous carcinoma     64 (37.0)   42.9  25 
    Mixed carcinoma                          16 (9.2)                      25    0 
Tab 2  Comparison of different subtypes in 173 NSCLC-N2 cases 
                    
      Unexpected   
                                     IIIa (T1, T2, T3)  Proven                                   
 Bulky        IIIb (T4)
                                                NAT+O                               O                            NAT   
Cases                                    46                                22                               39                                8                  12  46
1 station                           34 (73.9%)  36 (52.2%)    2 (16.7%)  19 (41.3%)
≥2 station                          12 (26.1%)  33 (47.8%)  10 (83.3%)  27 (58.7%)
Complete resection      40 (87.0%)  47 (77.0%)     3 (25.0%)  20 (43.8%)
5-year survival (%)            30.4                               27.3                               17.9                              12.5                  0.0  11.1%
Tab 3  Comparison of lobectomy and pneumonectomy 
                           Lobotectomy  Pneumonectomy
Cases                                     125               27
5-year survival rate (%)                23.2              14.8
Percentage of T4 (%)             16.0              44.4
∆FEV1↓                                    14.7%              32.3%
Pneumonia              9 (7.2%)                    3 (11.1%)
Respiratory failure              7 (5.6%)                    2 (7.4%)
Heart failure              5 (4.0%)                    3 (11.1%)
Bleed                                   5 (4.0%)                     2 (7.4%)
Pulmonary embolism           4 (3.2%)          2 (7.4%)
Arrhythmia          20 (16.0%)          3 (11.1%)
Tab 4  Multivariate Cox proportional Hazard Analysis of 5-year survival rate
Variable                            Regression coefficient     Relative risk       95%CI     P 
Complete resection                      -0.903               0.407          0.206-0.797     0.009
Uncomplete resection  0.752               2.03            1.051-3.814  0.039
T4                                            0.646               1.909         1.020-3.572  0.043
T3                                            0.053               1.054         0.545-2.038  0.875
Signal station                     -0.932               0.374         0.185-0.772  0.008
Multiple stations                       0.551               1.786         0.874-3.129  0.052
Fig 1  Kaplan-Meier analysis of survival rates based on operation 
methods for 173 patients with N2 NSCLC diseases
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Fig 2   Kaplan-Meier analysis of survival rates based on T status  
            for 173 patients with N2 NSCLC diseases
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to decide surgical indication and provide the best combined 
therapy. N2 NSCLC belongs to locally advanced cancer and 
has a 7-month natural median survival time. Patients who are 
not suitable to resection, the standard treatment pattern is che-
motherapy (platinum contained) plus radiotherapy. Median 
survival time with synchronic chemoradiation therapy is 17 
months, with 5-year survival rate reaching 16%. Median surviv-
al time with sequential chemoradiation therapy is 13 months, 
and its 5-year survival rate is 9%
[1]. In order to maximize the 
long-term rate of N2 patients, we need to explore proper surgi-
cal treatment. Combined with related report, our series is to 
analyze the result of our survey so as to probe into the factors 
influencing prognosis and possible reasons, as well as clarifying 
conditions under which surgical options are made.
Clinical characteristics and prognosis
The 5-year survival rate in those whose age was above 60 
years (12.5%) was less than that of patients whose age were 
under 60 years (27.8%), P=0.88. The survival rate for male 
(12.1%) was less than female (44.4%), but the percentages 
have no statistic value, P=0.15. Just as Vansteenkiste et al
[2] re-
ported, age and gender cannot be seen as independent factors 
decisive to the prognosis.
Surgical treatment and Prognosis
Theoretically, N2 NSCLC patients could be classified as 
resectable and unresectable by pre-surgical evaluation. The 
resectable group covers the following subgroups. First, the 
unexpected N2 (Cases classified as stage I, II of CTNM before 
operation then discovered with mediastinal lymph node me-
tastasis after operation). Second, single or multiple mediastinal 
lymph node metastasis testified through radiology and could 
be fully removed (The key point of distinguishing whether the 
enlarge lymphondes invade normal structures or not is to see 
if there is a low density zone between them through chest CT. 
The zone always indicates a layer of fat and all lymphondes can 
always be completely eliminated after softly inactively dissec-
tion during operation). Third, a portion of T4 cases. The unre-
sectable group includes N2 proven before surgery, the positive 
cases with mediastinal mass-like density shown by radiology, 
and proven by mediastinoscopy (edge III stage) and most of 
T4.
In term of the surgical character, 4 types can be classified: 
(1) Complete resection: 4 conditions must be meted. First, all 
the incisal edges (including the bronchus, artery, vein, tissues 
around the bronchus and the primary tumor) are negative (free 
of tumor cells) under the microscope. Second, systematic or 
lobe systematic lymph nodes dissection should be done, and 
6 groups must contained, 3 locate in the lobe (lobar, interlobe 
or segmental lymph node) and hilar, the other 3 are mediasti-
nal lymph nodes (subcarinal included). Third, no invasion is 
found out of the lymph nodes in the dissected mediastinal or 
lobe marginal nodes. Fourth, the highest mediastinal lymph 
nodes must be resected, and should be negative under the mic-
toscope. (2) Uncomplete resection: tumor cells were left on 
the cutting edge, invasion out of the lymph nodes was found 
in mediastinal or lobe's marginal lymph nodes. Lymph nodes 
were positive with tumor cells, but cannot be dissected, carci-
noma cells were found in the pleura or pericardium effusion. 
(3) Uncertain resection: no evidence of the residual tumor, 
but the operation can not meet the criterion of complete resec-
tion, that is, all the cut-edge are negative under the microscope, 
but one of the following situations come up, carcinoma in situ 
is found on the cut-edge, lymph nodes dissection can not meet 
the criterion mentioned above, the highest mediastinal lymph 
nodes are positive but are already be dissected, tumor cells are 
found in the washing liquor from the pleura cavity. (4) Ex-
plore: the thoracic was only opened, but tumor tissues can not 
be resected or only biopsy was applied. 
The retrospective research of our series indicates that for 
N2 cases selected above, the rate of resection was 66.7%, 5-year 
survival rate was 23.6%, significantly higher than that of sur-
gery of other natures, and the survival curve was show in Fig 1.
Surgeries consist of lobectomy and pneumonectomy, The 
analysis of this series suggests that patients who had lobectomy 
(104 standard operations, 12 sleeve resection included and 9 
lobectomy under thoracoscope) have a higher 5-year survival 
rate of 23.2% than 14.8% for patients who had pneumonec-
tomy (P<0.01) . 
We attribute this to following factors. First, pneumonec-
tomy compromise more lung factions (Tab 3. Six months after 
the lobectomy, FEV1 was reduced by 14.7%, pneumonectomy 
dropped by 32.3%). Second, T stage of primary tumor in 
pneumonectomy was later; the rate of T4 rate was enormously 
increased (44%). Third, the rate of complication for pneumo-
nectomy was higher, including pneumonia (11.1%), respira-
tory failure (7.4%), heart failure (11.1%), bleeding (7.4%), 
pulmonary embolism (7.4%), cardiac arrhythmia (11.1%). 
Kiser
[3] also verified that resection is a risk factor for prognosis. 
Therefore, with techniques workable/available, sleeve resec-
tion instead of pneumonectomy is recommended.
T status and prognosis
Mountain
[4]and Regnard et al
[5]reported that the earlier the 
T stage, the better the prognosis. In our series research, the 
surgical indication for N2 NSCLC was based on two criteria: 
no invasion of the pleura by the tumor, a distance between the 
margin of the tumor and carina of more than 2 cm (T1 and 
T2). Patients belonging to this stage had a better 5-year sur-
vival rate (37.5%) than T4 patients (11.1%, P=0.01). 
The criterion of choosing T4 patients for operation are 
as follows: (1) The pulmonary artery, vein, bronchus and 
these branches are evaluated can be dissected through chest 
enhancement CT. (2) Sleeve resection can be carried out 
through the observation from bronchoscope (mostly upper 
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lobe sleeve resection for squamous carcinoma). (3) No more 
than 1/3 of the SVC (superior vena cava) is invaded, and then 
the blood vessel plasty by patch or reconstruction operation 
can be done. (4) The atrium is invaded, but the defected part 
can be sewed up or patched by a part of pericardium. (5) Only 
the external membrance of the aorta is invaded, the function 
of blood vessel’s wall is basically not affected after tumor re-
moved. (6) Metastasis nodes are found in the same lobe. The 
specific distribution of the cases: carina invaded (n=10), SVC 
(n=4), atrium (n=7), aorta (n=3), metastasis nodes are found 
in the same lobe (n=8). Invasion of the vertebra, esophagus, 
trachea and maligment pleura effusion are nit included.
If patients could be selected with the consideration of the 
standard above, surgery can reduce tumor, mitigate coughing, 
chest pain and chest tightness, improving patients’ living qual-
ity. However, since the rate of uncomplete resection (15.6%) 
is much higher than that of T1/T2 (2%) and T3 (5.9%), it has 
very limited effect to long-term survival rate. Therefore, surgery 
is not a proper option for T4 patents and needs to be adopted 
carefully.
Medastinal lymph node metastasis and prognosis 
Ishida
[6] figured out through research that probabilities of 
lymph node metastasis for tumors with radius lesser than 1 
cm, 1.1 cm to 2 cm, 2.1 cm to 3 cm are 0%, 17% and 38% re-
spectively. The standard of pheumoecotomy requires not only 
lobecotomy where primary tumor is, but also the complete 
removal of mediastinal lymph node, otherwise the recurrence 
rate will be increased.
In this paper, N2 is classified into 4 subgroups. The first 
group is Unexpected N2 (incidental or surprised N2), which 
belongs to period I or II clinical stage classification, yet is 
found out to be N2 metastasis through pathology after opera-
tion or single station mediastinal lymph node metastasis dur-
ing operation. The second group is marginal or proven N2. 
There is mediastinal mass-like density on the basis of radiology 
before surgery, and single or multiple lymph node metastasis 
proven through mediastinoscopy, PET/CT, or lymph biopsy. 
The third group is Bulky N2 with short radius  more than 2 
cm or stable lymph matastasis of multiple stations. The fourth 
group is N2 with primary as T4. The percentages of single 
station lymph node and the rate of pneumoecotomy is much 
higher for unexpected N2 and proven N2 discovered before 
surgery and is down-staged by neoajuvant therapy, compared 
with bulky N2 and N2 with primary tumor as T4. 5-year sur-
vival rates for unexpected N2 and N2 proven and down-staged 
ahead of surgery are 30.4 % and 27.3%, substantially higher 
than other N2 types (P<0.01). 5-year survival rate for single-
station lymph node metastasis is 27.8%, significantly higher 
than 9.3% for  multiple-station one (P<0.01).
Patients with single mediastinal N2 featuring in enlarged 
and removable lymph node are recommended to apply a com-
bination of neoadjuvant chemotherapy, surgery chemotherapy 
-or radiotherapy, which is consistent with Kara’s
[7] view. For 
multiple-station N2 or bulky N2 could be divided into resect-
able and unresectable ones. The effect after the resection is 
unfavorable and non-surgical methods should dominate the 
treatment.
Pathological characteristics and prognosis
Arguments still exists on the relation of these two factors. It 
is reported that adenocarcinoma cells are prone to metastasis 
(v) through blood and lymph systems, the long-term survival 
time of squamous cell carcinoma patients was longer than oth-
er patients (adenocarcinoma included). However, in the per-
spective of statistics, there was no difference in survival time 
for those with squamous cell carcinoma (25.0%) and those ad-
enocarcinoma (8.3%) in our study (P>0.05). Additionally, the 
rate for mixed carcinoma, big-cell cancer and others were 0.0%, 
0.0% and 33.3%. The reason is still unknown, but one likely 
explanation may be that follow-up was conducted on a limited 
number of patients.
Adjuvant therapy and prognosis
Pre-surgical chemotherapy
The current randomized controlled studies shows that pre-
surgical neoadjuvant is beneficial to long-term survival for 
N2 patients. There are 5 RCTs which illustrate that the 5-year 
survival rate for those who had chemotherapy before their sur-
geries were 28%, yet that of those who had surgeries only were 
16%. The difference in 2 related studies has statistical indica-
tion
[8].
The reason for this is that chemotherapy can downgrade the 
stage of tumors, thus facilitates the radical treatment. Pre-surgi-
cal chemotherapy could raise the 5-year survival rate from 14% 
to 20%
[9], according to the meta analysis in 12 clinical research 
conducted by Burddet in 2006. It is proved in our research that 
pre-surgical neoadjuvant chemotherapy can down-stage N2 
status and gain patients chances of operations, increasing their 
5-year survival rate from 17.9% to 27.3%.
Post-surgical chemotherapy
It is arguable whether patients should have chemotherapy 
after surgeries and how many chemotherapy are reasonable. 
Most people agree that consolidate the chemotherapy scheme 
is necessary. Nevertheless, Scoinski
[10] regards that extending 
post-surgical periods can not improve survival time. On con-
trary, it increases the toxics of chemotherapy and compromise 
quality of patients’ life.
Socinski
[10] reports that the 5-year survival rate of locally 
advanced NSCLC with the 3
rd generation of cisplatin-based 
chemotherapy after surgeries is 37%, higher than 32%, the rate 
of those without the chemotherapy (P<0.05). Similarly, re-
searches done by ANITA
[11] indicates that NP scheme adjvant 
chemotherapy prolongs patients’ survival time.
In our series, 101 patients underwent post-surgical chemo-
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therapy, 5-year survival rate was 35% for those had 4 durations 
of post-chemotherapy, higher than 18.8%, the rate of those 
without the post-surgical therapy. The patients who had post-
surgical chemotherapy lasting less or more than 4 durations 
were 14.3% and 333.3% respectively. However, these percent-
ages don’t have statistical indication. It suggests that post-sur-
gical chemotherapy did not play an effective role in reducing 
the recurrence rate and raising survival rate without recurrence 
recurrence-free survival rate. According to the result from 3 
random clinical comparative research conveyed by Socinski
[12], 
for those who had 2-4 durations of chemotherapy and those 
who had 6 or more durations of chemotherapy, the survival 
rates are almost the same. Moreover, the toxic and side effects 
of chemotherapy will be reduced by limit the number of dura-
tions and it is recommended that 4 duration chemotherapy 
after operation should be the optical solution.
It is worthy of notice that pneumoectomy, especially the 
right pneumoectomy takes a long time for recovery and is 
not suitable for adjuvant therapy. This view is shared by Yilon 
Wu
[13].
Radiotherapy
In our series, 5-year survival rate of the patients with and 
without the radiotherapy were 6.3% and 26.9% (P=0.317).
Despite of the disparity in the percentages, there is no obvious 
difference in statistic views in that patients who had pallia-
tive resection accounted for a large percentage of the overall 
patients in the post-surgical radiotherapy group. Local recur-
rence rate as high as 19% to 29% was seen in patients who 
had non-standard dissection of lymph nodes (the number of 
dissections is less than 3 stations, especially with the 7
th lymph 
node included), extra-capsular spread/invasion in lymph node, 
multiple N2 metastasis and less than 2 cm’s distance between 
tumor and resection margin of bronchus. They are high risk 
group of patients
[14]. 
Cochrane system, conversely, it is proved that post-surgical 
radiotherapy reduces the local recurrence rate, yet it has nega-
tive influence on survival rate and increases the risk of death by 
21%, which is equal to cutting down the 2-year survival rate by 
7%, lowering the overall survival rate from 55% to 48%
[15].
Whereas Sawyer
[16] proposes the idea that post-surgical 
radiotherapy may improve long-term survival time for N2 pa-
tients, hence whether post-surgical radiotherapy can increase 
overall survival rate remains controversial for those who had 
incomplete resection. Now that adjuvant radiotherapy brings 
down overall survival rate, it is not recommended to the pa-
tients with complete resection.
In summary, we have reached the conclusion that among the 
factors influencing prognosis of N2 NSCLC patients, surgery 
is the best option for T1 and T2 patients whose primary tumor 
had been detected before surgery with the tumor not invading 
the pleura and the distance between the tumors and tracheal 
carina is no less than 2 cm, patients who are with negative me-
diastinal lymph node and found single station N2 removable 
during surgery, patients with N2 proven before surgery but 
down-staged by neoaduevant chemotherapy. The best surgical 
type is lobectomy which cause less incidence of complication 
and death compared with pneumoectomy. Patients’ survival 
time will not benefit from surgery if they are with lymph nodes 
metastasis of multiple stations (Bulky N2 included) and T4 
which can be partially removed. Neoadjuvant chemotherapy 
increases long-term survival rate of those with N2 proven prior 
to surgery. However, post-surgical radiotherapy decreases local 
recurrence rate but does not contribute to patients’ long-term 
survival rate.
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